E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Functional Constipation |
Stipsi funzionale |
|
E.1.1.1 | Medical condition in easily understood language |
Functional Constipation is a condition that manifests with the following symptoms: infrequent, hard stools, and painful defecation. |
La stipsi funzionale è una condizione che si manifesta con i seguenti sintomi: infrequenza, feci dure e defecazione dolorosa. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10010774 |
E.1.2 | Term | Constipation |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety, tolerability and efficacy of 12 weeks of linaclotide therapy in comparison with placebo in pediatric participants, 6 to 17 years of age, who fulfill modified Rome III Criteria for Child/Adolescent FC |
Valutare la sicurezza, la tollerabilità e l’efficacia di una terapia con linaclotide di 12 settimane in confronto al placebo in pazienti pediatrici tra 6 e 17 anni che soddisfano i criteri Rome III modificati per FC in bambino/adolescente |
|
E.2.2 | Secondary objectives of the trial |
Not applicable |
Non applicabile |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Age and Weight 1.01 Male and female participants must be ages 6 to 17 years, (inclusive) at the time the participant provides assent for the study and parent/guardian/legally authorized representative (LAR) has provided signed consent 1.02 Participant weighs >=18 kg at the time the parent/guardian/LAR has provided signed consent 2.Type of Participant and Disease Characteristics 2.01 Participants who meet the modified Rome III criteria for Child/Adolescent FC. For at least 2 months before the Screening Visit, the participant has had 2 or fewer defecations in the toilet per week and, in addition, meets 1 or more of the following criteria: a. History of retentive posturing or excessive volitional stool retention (at least once per week) b. History of painful or hard BMs (at least once per week) c. History of large diameter stools that may obstruct the toilet (at least once per week) d. Presence of a large fecal mass in the rectum e. At least 1 episode of fecal incontinence per week 2.02 Participant is willing to discontinue any laxatives used before the Preintervention Visit in favor of the protocol- permitted rescue medicine. 2.03 Participant has an average of fewer than 3 SBMs per week during the 14 days before the randomization day and up to the randomization (including the morning eDiary assessments reported before administration of first dose of double-blind study intervention on the randomization day). An SBM is defined as a BM that occurs in the absence of laxative, enema, or suppository use on the calendar day of the BM or the calendar day before the BM 2.04 Participant or parent/guardian/LAR or caregiver is compliant with eDiary requirements by completing both the morning and evening assessments for 10 out of the 14 days immediately preceding the Randomization Visit 3.Contraceptives 3.01 Female participants of childbearing potential must have a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test at the Randomization Visit prior to dosing 3.02 Female participants who have had their first menstrual period and are sexually active must agree to use a reliable form of contraception. Reliable contraception is defined in Section 10.7 Appendix 7. 4.Informed Consent 4.01 Participant must provide written or verbal informed assent and the parent/guardian/LAR and caregiver must provide written informed consent before the initiation of any study-specific procedures 4.02 Participant is able to read and/or understand the assessments in the eDiary device. If the participant is 6 to 11 years of age and does not meet this criterion, the interviewer-administered version of the eDiary must be used and the parent/guardian/LAR or caregiver who will be administering the interviewer-administered version of the eDiary must undergo training 5.Other 5.01 Participant must have acquired toilet training skills |
Si prega di fare riferimento alla sezione E.3.EN |
|
E.4 | Principal exclusion criteria |
Si prega di fare riferimento al protocollo causa limite massimo numero di caratteri consentito. |
Si prega di fare riferimento al protocollo causa limite massimo numero di caratteri consentito. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change from baseline in 12-week SBM frequency rate (SBMs/week) during the study intervention period |
La modifica rispetto al basale nel tasso di frequenza di SBM (SBM/settimana) a 12 settimane durante il periodo interventistico dello studio |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At week 12 |
Alla settimana 12 |
|
E.5.2 | Secondary end point(s) |
Change from baseline in 12-week stool consistency during the study intervention period; Safety and tolerability assessments |
La modifica rispetto al basale nella consistenza delle feci per 12 settimane durante il periodo interventistico dello studio; Valutazione della sicurezza e della tollerabilità |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At Week 12; At Week 12 |
Alla settimana 12; Alla settimana 12 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 50 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
Israel |
Serbia |
Ukraine |
United States |
Belgium |
Bulgaria |
Estonia |
Germany |
Hungary |
Italy |
Netherlands |
Poland |
Spain |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | 8 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 5 |
E.8.9.2 | In all countries concerned by the trial days | 0 |